Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
inFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.